Cutler Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-2,200
| Closed | -$82K | – | 6758 |
|
|
2021
Q1 | $82K | Buy |
+2,200
| New | +$54.9K | ﹤0.01% | 1941 |
|
|
2019
Q4 | – | Sell |
-284
| Closed | -$1K | – | 4902 |
|
|
2019
Q3 | $1K | Hold |
284
| – | – | ﹤0.01% | 3928 |
|
|
2019
Q2 | $1K | Sell |
284
-5,300
| -95% | -$50.7K | ﹤0.01% | 4098 |
|
|
2019
Q1 | $74K | Buy |
5,584
+3,584
| +179% | +$40.9K | 0.01% | 1182 |
|
|
2018
Q4 | $18K | Buy |
+2,000
| New | +$23.8K | ﹤0.01% | 2196 |
|
|
2018
Q2 | – | Sell |
-1,951
| Closed | -$34K | – | 5182 |
|
|
2018
Q1 | $33K | Sell |
1,951
-3,673
| -65% | -$71.6K | ﹤0.01% | 1954 |
|
|
2017
Q4 | $123K | Buy |
5,624
+4,037
| +254% | +$130K | 0.01% | 1255 |
|
|
2017
Q3 | $64K | Sell |
1,587
-1,684
| -51% | -$52.9K | ﹤0.01% | 2025 |
|
|
2017
Q2 | $98K | Buy |
3,271
+1,466
| +81% | +$45.8K | ﹤0.01% | 1876 |
|
|
2017
Q1 | $65K | Sell |
1,805
-8,029
| -82% | -$354K | ﹤0.01% | 2137 |
|
|
2016
Q4 | $492K | Buy |
9,834
+9,133
| +1,303% | +$480K | 0.02% | 701 |
|
|
2016
Q3 | $36K | Sell |
701
-2,512
| -78% | -$120K | ﹤0.01% | 2796 |
|
|
2016
Q2 | $132K | Sell |
3,213
-9,002
| -74% | -$392K | 0.01% | 1454 |
|
|
2016
Q1 | $496K | Buy |
12,215
+7,470
| +157% | +$257K | 0.03% | 528 |
|
|
2015
Q4 | $196K | Buy |
+4,745
| New | +$159K | 0.01% | 1201 |
|
Cutler Group's FPRX Position: Q2 2021 in Review
Cutler Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 2,200 shares — an estimated $82K sold.
Cutler Group first reported a position in FPRX in Q4 2015 and held it in 15 quarters. The position peaked at $496K in Q1 2016. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Cutler Group reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Cutler Group sold 2,200 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $82K.
- Cutler Group first reported a position in Five Prime Therapeutics, Inc. in Q4 2015 and held it in 15 quarters.
- Cutler Group's Five Prime Therapeutics, Inc. position peaked at $496K in Q1 2016.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Cutler Group's 13F filing for Q2 2021, filed 19 Jul 2021.